Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

While the broader stock market suffered steep losses amid trade policy shifts select health technology equities stood out.